Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Neoplasms 2Advanced Solid Neoplasm 2Solid Tumors 1Renal Insufficiency 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma 1Lymphoma 1Lung Neoplasms 1Liver Diseases 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Pemetrexed 12Cisplatin 11pembrolizumab 8Carboplatin 6Ipilimumab 5Nivolumab 4LMB-100 4durvalumab 3Gemcitabine 3tremelimumab 2tazemetostat 2anetumab ravtansine 2Vinorelbine 2Plicamycin 2Dexamethasone 2Cyclophosphamide 2Bevacizumab 2vandetanib 1tocilizumab 1spartalizumab 1ribociclib 1rebastinib 1pevonedistat 1olaparib 1niraparib 1nintedanib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mesothelioma × pevonedistat × Clear all
NCT03319537 2024-05-23

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
9 enrolled 9 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡